Studies have identified over 42% of Americans are obese. The scope of the U.S. weight demographic explains the explosion of sales of GLP-1 drugs with 12% of the population trying the drugs. Although significant weight-loss results have been identified, 50% of consumers stop using the GLP-1 prescribed drug in the first year with another 25% of patients ceasing its use by the second year, resulting in 75% of consumers ending the use of their prescriptions. As a result consumers have experienced their weight returning.
Studies have shown a range of side effects and even serious complications as a result of the currently approved GLP-1 drugs.1 The documented side effects are predominantly gastrointestinal, and include nausea, diarrhea, constipation, vomiting and include a loss of muscle mass. There are reported adverse events, that include gallbladder disorders and acute pancreatitis.2 In addition, multiple studies identified new risks associated with GLP-1RAs including increased aspiration risk during anesthesia due to delayed gastric emptying and bowel preparation for colonoscopies.
Recent studies on gut bacteria Akkermansia muciniphila have demonstrated its influence on GLP-1 natural production and weight loss.3 Research has also suggested that berberine, a naturally occurring compound in several plants may stimulate the release of GLP-1 and help improve glycemic control, reduce appetite, and support weight loss, making it a promising supplement for managing type 2 diabetes and metabolic disorders.4 Its combination of effects on glucose metabolism and GLP-1 release makes berberine a valuable natural option for metabolic health.
Plant Science uses the latest studies to enhance product development for your consumers.
